Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amylyx Pharmaceuticals Inc ( (AMLX) ) just unveiled an update.
On August 27, 2025, Amylyx Pharmaceuticals announced the discontinuation of its ORION program for AMX0035 in adults with progressive supranuclear palsy, as the drug showed no significant differences compared to placebo in primary or secondary outcomes at Week 24. Consequently, the company will halt the Phase 2b trial and open-label extension, and will not proceed with the Phase 3 portion, although safety data remained consistent with previous studies.
The most recent analyst rating on (AMLX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.
Spark’s Take on AMLX Stock
According to Spark, TipRanks’ AI Analyst, AMLX is a Neutral.
The overall stock score of 53 reflects significant financial challenges, including declining revenues and operational losses, which weigh heavily on the company’s financial health. However, positive technical indicators suggest some market optimism, and the company’s strong cash position and pipeline progress provide a foundation for potential future growth. Valuation remains a concern due to negative earnings, highlighting the need for improved profitability.
To see Spark’s full report on AMLX stock, click here.
More about Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing treatments for neurodegenerative diseases. Its primary product, AMX0035, is a combination of sodium phenylbutyrate and taurursodiol, aimed at treating conditions like progressive supranuclear palsy.
Average Trading Volume: 1,461,550
Technical Sentiment Signal: Buy
Current Market Cap: $816.8M
For an in-depth examination of AMLX stock, go to TipRanks’ Overview page.